+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Hemophilia A Therapeutics Market 2019-2023 - Product Image

Global Hemophilia A Therapeutics Market 2019-2023

  • ID: 4721336
  • Report
  • December 2018
  • Region: Global
  • 120 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Bayer
  • CSL
  • Novo Nordisk
  • Pfizer
  • Shire
  • MORE
Emerging novel convenient approaches to drive market growth. Several novel therapies are emerging in the global hemophilia A therapeutics market. These therapies offer long lasting therapeutics benefits and some of the m possess potential to cure this disorder. The analysts have predicted that the hemophilia A therapeutics market will register a CAGR of almost 7% by 2023.

Market Overview

Rising prevalence of hemophilia A

Hemophilia A is a rare genetic disorder, and the incidence of this disorder is gradually increasing. Hemophilia A accounts for about 80% of cases globally and mainly affects men.

High costs of hemophilia A therapeutics

High costs associated with drugs that treat hemophilia A are one of the biggest challenges faced by the market.

For the detailed list of factors that will drive and challenge the growth of the hemophilia A therapeutics market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Pfizer and Shire, the competitive environment is quite intense. Factors such as the emerging novel convenient approaches and the rising prevalence of hemophilia A, will provide considerable growth opportunities to hemophilia A therapeutics manufactures. Bayer, CSL, Novo Nordisk, Pfizer, and Shire are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer
  • CSL
  • Novo Nordisk
  • Pfizer
  • Shire
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Recombinant therapies - Market size and forecast 2018-2023
  • Plasma-derived therapies - Market size and forecast 2018-2023
  • Hormonal therapies - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE
  • On demand treatment
  • Prophylactic treatment
  • Inhibitor treatment
PART 10: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer
  • CSL
  • Novo Nordisk
  • Pfizer
  • Shire
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global rare disease market
Exhibit 03: Segments of global rare disease market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Pipeline molecules for hemophilia A
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Recombinant therapies - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Recombinant therapies - Year-over-year growth 2019-2023 (%)
Exhibit 23: Plasma-derived therapies - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Plasma-derived therapies - Year-over-year growth 2019-2023 (%)
Exhibit 25: Hormonal therapies - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Hormonal therapies - Year-over-year growth 2019-2023 (%)
Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Others - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 35: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 37: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Decision framework
Exhibit 42: Manufacturer Co-Pay Programs
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Bayer - Vendor overview
Exhibit 50: Bayer - Business segments
Exhibit 51: Bayer - Organizational developments
Exhibit 52: Bayer - Geographic focus
Exhibit 53: Bayer - Segment focus
Exhibit 54: Bayer - Key offerings
Exhibit 55: CSL - Vendor overview
Exhibit 56: CSL - Business segments
Exhibit 57: CSL - Organizational developments
Exhibit 58: CSL - Geographic focus
Exhibit 59: CSL - Segment focus
Exhibit 60: CSL - Key offerings
Exhibit 61: Novo Nordisk - Vendor overview
Exhibit 62: Novo Nordisk - Business segments
Exhibit 63: Novo Nordisk - Organizational developments
Exhibit 64: Novo Nordisk - Geographic focus
Exhibit 65: Novo Nordisk - Segment focus
Exhibit 66: Novo Nordisk - Key offerings
Exhibit 67: Pfizer - Vendor overview
Exhibit 68: Pfizer - Business segments
Exhibit 69: Pfizer - Organizational developments
Exhibit 70: Pfizer - Geographic focus
Exhibit 71: Pfizer - Segment focus
Exhibit 72: Pfizer - Key offerings
Exhibit 73: Shire - Vendor overview
Exhibit 74: Shire - Business segments
Exhibit 75: Shire - Organizational developments
Exhibit 76: Shire - Geographic focus
Exhibit 77: Shire - Key offerings
Exhibit 78: Validation techniques employed for market sizing
Exhibit 79: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Bayer
  • CSL
  • Novo Nordisk
  • Pfizer
  • Shire
  • MORE
Global Hemophilia A Therapeutics Market 2019-2023

The analyst recognizes the following companies as the key players in the global hemophilia A therapeutics market: Bayer, CSL, Novo Nordisk, Pfizer, and Shire.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the emerging novel convenient approaches.”

According to the report, one of the major drivers for this market is the rising prevalence of hemophilia A.

Further, the report states that one of the major factors hindering the growth of this market is high costs of hemophilia A therapeutics.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bayer
  • CSL
  • Novo Nordisk
  • Pfizer
  • Shire
Note: Product cover images may vary from those shown
Adroll
adroll